Skip to main content

Table 2 Clinical outcomes according to DM/CKD subgroup

From: Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial

 

DM (-) CKD (-)

DM ( +) CKD (-)

DM (-) CKD ( +)

DM ( +) CKD ( +)

Ptrend

n = 10,513

HR (95% CI)

HR (95% CI)

n = 1332

HR (95% CI)

n = 838

HR (95% CI)

All-cause mortality or New Q-wave MI

330 (3.1%)

1.00 (Ref)

1.32 (1.07–1.61)

92 (6.9%)

1.54 (1.21–2.49)

80 (9.5%)

1.91 (1.47–2.49)

 < 0.001

 All-cause mortality

226 (2.1%)

1.00 (Ref)

1.37 (1.08–1.75)

74 (5.6%)

1.67 (1.27–2.81)

67 (8%)

2.09 (1.55–2.81)

 < 0.001

 New Q-wave MI

108 (1%)

1.00 (Ref)

1.29 (0.9–1.86)

19 (1.4%)

1.19 (0.72–2.3)

13 (1.6%)

1.26 (0.69–2.3)

0.257

Stroke

78 (0.7%)

1.00 (Ref)

1.86 (1.28–2.71)

18 (1.4%)

1.17 (0.68–3.48)

19 (2.3%)

2.04 (1.19–3.48)

0.013

MI

273 (2.6%)

1.00 (Ref)

1.48 (1.18–1.85)

52 (3.9%)

1.61 (1.18–3.49)

53 (6.3%)

2.54 (1.85–3.49)

0.001

Any Revascularization

917 (8.7%)

1.00 (Ref)

1.26 (1.11–1.43)

129 (9.7%)

1.17 (0.96–1.91)

113 (13.5%)

1.55 (1.26–1.91)

 < 0.001

 TVR

466 (4.4%)

1.00 (Ref)

1.5 (1.27–1.78)

71 (5.3%)

1.28 (0.99–2.37)

67 (8.0%)

1.8 (1.38–2.37)

 < 0.001

Definite stent thrombosis

82 (0.8%)

1.00 (Ref)

1.08 (0.69–1.7)

13 (1.0%)

1.43 (0.78–2.23)

6 (0.7%)

0.94 (0.4–2.23)

0.569

MACE

394 (3.7%)

1.00 (Ref)

1.43 (1.19–1.71)

101 (7.6%)

1.4 (1.11–2.42)

93 (11.1%)

1.9 (1.49–2.42)

 < 0.001

POCE

1242 (11.8%)

1.00 (Ref)

1.3 (1.17–1.45)

219 (16.4%)

1.3 (1.12–2.06)

194 (23.2%)

1.75 (1.49–2.06)

 < 0.001

NACE

1360 (12.9%)

1.00 (Ref)

1.27 (1.15–1.41)

245 (18.4%)

1.29 (1.12–2.03)

213 (25.4%)

1.74 (1.49–2.03)

 < 0.001

BARC 3 or 5 bleeding

188 (1.8%)

1.00 (Ref)

1.05 (0.78–1.41)

44 (3.3%)

1.18 (0.83–2.39)

37 (4.4%)

1.64 (1.12–2.39)

0.02

 BARC 5 bleeding

27 (0.3%)

1.00 (Ref)

0.51 (0.2–1.3)

8 (0.6%)

1.16 (0.5–2.09)

5 (0.6%)

0.71 (0.24–2.09)

0.704

 BARC 3 bleeding

173 (1.6%)

1.00 (Ref)

1.12 (0.83–1.52)

41 (3.1%)

1.22 (0.85–2.71)

35 (4.2%)

1.84 (1.25–2.71)

0.005

   BARC 3a bleeding

77 (0.7%)

1.00 (Ref)

1.31 (0.85–2.01)

25 (1.9%)

1.64 (1.02–2.63)

13 (1.6%)

1.42 (0.76–2.63)

0.054

   BARC 3b bleeding

74 (0.7%)

1.00 (Ref)

1.01 (0.62–1.64)

17 (1.3%)

1.29 (0.73–3.71)

14 (1.7%)

2.02 (1.1–3.71)

0.043

   BARC 3c bleeding

38 (0.4%)

1.00 (Ref)

0.78 (0.37–1.65)

3 (0.2%)

0.38 (0.11–4.56)

10 (1.2%)

2.11 (0.98–4.56)

0.524

BARC 2 bleeding

489 (4.7%)

1.00 (Ref)

1 (0.83–1.21)

82 (6.2%)

1.07 (0.84–1.52)

54 (6.4%)

1.14 (0.85–1.52)

0.388

BARC 2, 3 or 5 bleeding

647 (6.2%)

1.00 (Ref)

1.01 (0.86–1.19)

118 (8.9%)

1.11 (0.9–1.62)

84 (10%)

1.27 (1–1.62)

0.063

  1. Data are n/N (%), unless otherwise specified
  2. MI, Myocardial ischemia
  3. TVR, Target vessel revascularization
  4. MACE, all-cause death, any stroke, or non-fatal new Q-wave MI
  5. POCE, all-cause death, any stroke, any myocardial infarction or any revascularization
  6. BARC, Bleeding Academic Research Consortium
  7. NACE, POCE and BARC 3 or 5 bleeding
  8. Adjusted to age, sex, body mass index (BMI), clinical presentation (ACS versus stable CAD), stroke, peripheral vascular disease (PVD), chronic obstructive pulmonary disease (COPD), previous PCI, hypercholesterolemia, hypertension, current smoking status, treatment regimen (experimental versus. reference regimen), complex PCI, ACEI or ARB, beta-blockade, statin, Paris thrombotic risk score, and Paris bleeding risk score